Deniz ÇETİN, Gökhan PEKTAŞ, Gökay BOZKURT, Füruzan Kacar DÖGER, İrfan YAVAŞOĞLU, Zahit BOLAMAN, Gürhan KADIKÖYLÜ

How is Aurora Kinase AExpression Altered in Chronic Lymphocytic Leukemia?

Aurora kinase A is an enzyme which regulates the maturation and separation of centrosomes and the assembly and stability of mitotic spindles during mitosis. The dysregulation of Aurora kinase A is related with aneuploidy and a pronounced increase in cancerrisk. This study aims to determine how the expression of Aurora kinase A is altered in chronic lymphocytic leukemia (CLL). This prospective case-control study reviewed 41 patients who were newly diagnosed with CLL and 18 patients with benign hematologicaldiseases. Bone marrow aspiration and biopsy were performed in all patients. Aurora kinase A expression in bone marrow cells was assessed by quantitative reverse transcriptase-polymerase chain reaction. Bone marrow specimens were immunohistochemically stained for Aurora-A antibody. Chromosomal abnormalities including 13q deletion, 17p deletion and trisomy 12 were investigated by fluorescence in situ hybridization in bone marrow aspirates of CLL patients. The CLL patients and the patients with benign hematological diseases were statistically similar in aspect of Aurora kinase A mRNA expression through β-actin and GAPDH housekeeping genes (respectively p=0.742 and p=0.229). Positive immunohistochemical staining for Aurora kinase A was significantly more frequent in CLL patients (p0.05 for all).Aurora kinase A may play a role in the pathogenesis of CLL but this role may not be as evident as it has previously been specified.

PDF

___

1.Choi MY, Kashyap MK, Kumar D. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor.Best Pract Res Clin Haematol. 2016; 29(1):40–53.

2.Galletti G, Caligaris-Cappio F, Bertilaccio MT. B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia. Leukemia. 2016; 30(12):2293–301.

3.Alsagaby SA, Brennan P, Pepper C. Key molecular drivers ofchronic lymphocytic leukemia. Clin Lymphoma MyelomaLeuk. 2016; 16(11):593–606.

4.Wang G, Jiang Q, Zhang C. The role of mitotic kinases in coupling the centrosome cycle with the assembly of the mitotic spindle. J Cell Sci. 2014; 127(Pt 19):4111–22.

5.Gavriilidis P, Giakoustidis A, Giakoustidis D. Aurora kinasesand potential medical applications of Aurora kinase inhibitors: A review. J Clin Med Res. 2015; 7(10):742–51.

6.Afonso O, Figueiredo AC, Maiato H. Late mitotic functions of Aurora kinases. Chromosoma. 2017; 126(1):93–103.

7.Sen S, Katayama H, Sasai K. Functional significance of Aurora kinase A in centrosome amplification and genomic instability. Adv Exp Med Biol. 2008; 617:99–108.

8.Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL Jr,Golemis EA. Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 2013; 70(4):661–87.

9.Wang Y, Sun H, Wang Z, et al. Aurora-A: a potential DNA repair modulator. Tumour Biol. 2014; 35(4):2831–6.

10. D'Assoro AB, Haddad T, Galanis E. Aurora-A Kinase as a promising therapeutic target in cancer. Front Oncol. 2016; 5:295.

11. Treekitkarnmongkol W, Katayama H, Kai K, et al. Aurorakinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis. 2016; 37(12):1180–9.

12. Zhang J, Li B, Yang Q, Zhang P, Wang H. Prognostic value of Aurora kinase A (AURKA) expression among solid tumor patients: a systematic review and meta-analysis. Jpn J Clin Oncol. 2015; 45(7):629–36.

13. Casey NP, Fujiwara H, Ochi T, Yasukawa M. Novelimmunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A. Oncoimmunology. 2016; 5(11): e1239006.

14. Wang LX, Wang JD, Chen JJ, et al. Aurora A kinase inhibitor AKI603 induces cellular senescence in chronic myeloidleukemia cells harboring T315I mutation. Sci Rep. 2016; 6: 35533.

15. Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2014; 32(3):489–99.

16. Aradottir M, Reynisdottir ST, Stefansson OA, et al. Aurora A is a prognostic marker for breast cancer arising in BRCA2mutation carriers. J Pathol Clin Res. 2014; 1(1):33–40.

17. Oliveira FM, Lucena-Araújo AR, Leite-Cueva SD, Santos GA, Rego EM, Falcão RP. Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype. Cancer Genet Cytogenet. 2010; 198(1):62–5.

18. Borges KS, Moreno DA, Martinelli CE Jr, et al. Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurorakinases A and B is associated with a poor prognosis. Pediatr Blood Cancer. 2013; 60(11):1809–16.

19. Shinmura K, Kiyose S, Nagura K, et al. TNK2 geneamplification is a novel predictor of a poor prognosis in patients with gastric cancer. J Surg Oncol. 2014; 109(3):189–97.

20. Koehrer S, Burger JA. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clin Adv Hematol Oncol. 2016; 14(1):55–65.

21. Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015; 94(3):193–205.

22. Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol. 2011; 155(5):561–79.

23. Durlacher CT, Li ZL, Chen XW, He ZX, Zhou SF. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor. Clin Exp Pharmacol Physiol. 2016; 43(6):585–601.

24. Inamdar KV, O'Brien S, Sen S, et al. Aurora-A kinase nuclear expression in chronic lymphocytic leukemia. Mod Pathol. 2008; 21(12):1428–35.

25. de Paula Careta F, Gobessi S, Panepucci RA, et al. The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets. Haematologica. 2012; 97(8):1246–54.

26. MacLean AL, Lo Celso C, Stumpf MP. Concise review: Stemcell population biology: Insights from hematopoiesis. StemCells. 2017; 35(1):80–8.

27. Jan M, Ebert BL, Jaiswal S. Clonal hematopoiesis. Semin Hematol. 2017; 54(1):43–50.

28.Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappa B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011; 117(2):563–74.

29. Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016; 1863(3):401–13.

30.Gry M, Rimini R, Strömberg S, et al. Correlations betweenRNA and protein expression profiles in 23 human cell lines.BMC Genomics. 2009; 10:365.

31. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999; 19:1720–30.

32. Tian Q, Stepaniants SB, Mao M, et al. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics. 2004; 3:960–9.

33. Mehra A, Lee KH, Hatzimanikatis V. Insights into the relation between mRNA and protein expression patterns: I.Theoretical considerations. Biotechnol Bioeng. 2003; 84:822–33.

34. Nie L, Wu G, Zhang W. Correlation of mRNA expressionand protein abundance affected by multiple sequence features related to translational efficiency in Desulfovibrio vulgaris: a quantitative analysis. Genetics. 2006; 174:2229–43.

35. Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2014; 32(3):489–99.